MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab plus daratumumab plus lenalidomide (EDR) versus daratumumab plus lenalidomide plus dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM)

被引：0

作者：

Kull, M. ^{[1
]}

Grosicki, S. ^{[2
]}

Yeh, S. -P. ^{[3
]}

Huang, J. S. Y. ^{[4
]}

Byun, J. M. ^{[5
]}

DiRienzo, C. ^{[6
]}

Viqueira, A. ^{[7
]}

机构：

[1] Univ Hosp Ulm, Dept Hematol, Ulm, Germany

[2] Med Univ Silesia, Dept Hematol & Canc Prevent, Katowice, Poland

[3] China Med Univ Hosp, Taichung, Taiwan

[4] Taiwan Univ Hosp, Taipei, Taiwan

[5] Seoul Natl Univ Hosp, Seoul, South Korea

[6] Pfizer Inc, New York, NY USA

[7] Pfizer SLU, Madrid, Spain

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1105

引用

页码：314 / 314

页数：1

共 50 条

[41] Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin
Anderson, Larry D., Jr.
Kaufman, Jonathan L.
Laubach, Jacob P.
Sborov, Douglas W.
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca W.
Costa, Luciano J.
Nathwani, Nitya
Shah, Nina
Bumma, Naresh
Holstein, Sarah A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Bartlett, J. Blake
Vermeulen, Jessica
Lin, Thomas S.
Voorhees, Peter M.
Richardson, Paul G.
BLOOD, 2021, 138
[42] Subcutaneous Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Therapy in Newly Diagnosed Multiple Myeloma After Transplant: Primary Results from the Phase 3 AURIGA Study
Badros, Ashraf
Foster, Laahn
Anderson, Larry
Chaulagain, Chakra
Pettijohn, Erin
Cowan, Andrew
Costello, Caitlin
Larson, Sarah
Sborov, Doug
Shain, Kenneth
Silbermann, Rebecca
Shah, Nina
Chung, Alfred
Krevvata, Maria
Pei, Huiling
Patel, Sharmila
Khare, Vipin
Cortoos, Annelore
Carson, Robin
Lin, Thomas S.
Voorhees, Peter M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S28 - S29
[43] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in newly diagnosed Multiple Myeloma (NDMM): analysis of vascular thrombotic events (VTEs) in the GRIFFIN study
Sborov, Douglas
Baljevic, Muhamed
Reeves, Brandi
Laubach, Jacob
Efebera, Yvonne
Rodriguez, Cesar
Costa, Luciano
Chari, Ajai
Silbermann, Rebecca
Holstein, Sarah
Anderson, Larry D., Jr.
Kaufman, Jonathan
Shah, Nina
Pei, Huiling
Patel, Sharmila
Cortoos, Annelore
Bartlett, Blake
Vermeulen, Jessica
Lin, Thomas
Voorhees, Peter
Richardson, Paul G.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S135 - S136
[44] Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Vs Ld in Patients with Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan
Takezako, Naoki
Ohta, Kensuke
Handa, Hiroshi
Hori, Mitsuo
Kinoshita, Gen
Shelat, Suresh
Miyoshi, Masafumi
Kubo, Kohmei
BLOOD, 2017, 130
[45] Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
Rajkumar, S. Vincent
Jacobus, Susanna
Callander, Natalie S.
Fonseca, Rafael
Vesole, David H.
Williams, Michael E.
Abonour, Rafat
Siegel, David S.
Katz, Michael
Greipp, Philip R.
LANCET ONCOLOGY, 2010, 11 (01): : 29 - 37
[46] A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study
Nooka, Ajay K.
Kaufman, Jonathan L.
Rodriguez, Cesar
Jakubowiak, Andrzej
Efebera, Yvonne
Reeves, Brandi
Wildes, Tanya
Holstein, Sarah A.
Anderson Jr, Larry D.
Badros, Ashraf
Shune, Leyla
Chari, Ajai
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Lin, Thomas S.
Richardson, Paul G.
Voorhees, Peter
FUTURE ONCOLOGY, 2022, 18 (40) : 4443 - 4456
[47] Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: The phase 1/2, prospective, open-label, BelaRd study
Terpos, Evangelos
Gavriatopoulou, Maria
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Spiliopoulou, Vasiliki
Syrigou, Rodanthi
Papaiakovou, Evangelos Eleutherakis
Gkolfinopoulos, Stavros
Manousou, Kyriaki
Kastritis, Efstathios
Dimopoulos, Meletios A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[48] Isatuximab, Plus Bortezomib, Lenalidomide, and Dexamethasone (VRd) for Newly Diagnosed Multiple Myeloma (NDMM) Transplant-ineligible Patients: Frailty Subgroup Analysis of IMROZ
Manier, Salomon
Dimopoulos, Meletios-Athanasios
Leleu, Xavier
Moreau, Philippe
Cavo, Michele
Goldschmidt, Hartmut
Orlowski, Robert Z.
Tron, Muriel
Tekle, Christina
Bregeault, Marie-France
Shafer, Andrea
Beksac, Meral
Facon, Thierry
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S290 - S291
[49] Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients.
Gay, Francesca
Rajkumar, S. Vincent
Falco, Patrizia
Kumar, Shaji
Dispenzieri, Angela
Gertz, Morie
Di Raimondo, Francesco
Lacy, Martha Q.
Crippa, Claudia
Buadi, Francis
Falcone, Antonietta
Hayman, Suzanne R.
Giuliani, Nicola
Short, Kristen E. Detweiler
Musto, Pellegrino
Roy, Vivek
Corradini, Paolo
Fonseca, Rafael
Petrucci, Maria Teresa
Greipp, Philip R.
Boccadoro, Mario
Stewart, A. Keith
Palumbo, Antonio
BLOOD, 2009, 114 (22) : 1123 - 1123
[50] Cost-Effectiveness of Daratumumab Plus Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: An Analysis of the Pollux Trial
Maiese, Eric M.
Graham, Christopher N.
Hawe, Emma
Le Moine, Jean-Gabriel
Abraham, Ivo
Senbetta, Mekre
BLOOD, 2017, 130

← 1 2 3 4 5 →